Inner Bubble 1
Inner Bubble 2
Inner Bubble 3
Posted in -
October 01, 2019
by - admin.

Veeda through its V-Konnect series interacted with Dr. Susobhan Das and discussed about “Current outlook of Biosimilar Development”   About the V- Konnect   V-Konnect interview series, is a program to get in touch with specialized industry experts to know their views on opinions on current relevant subject matters.   About Dr Susobhan Das – Founder […]

Posted in -
September 25, 2019
by - admin.

Introduced in the 1970s by Ralph A De Fronzo, Jordan Tobin, and Reubin Andres to quantify insulin secretion and resistance, glucose clamp studies are now considered the “gold standard” for studying pharmacodynamic and pharmacokinetics effects of different formulations of insulin. There are many variants of the glucose clamps such as the hyperinsulinemic-euglycemic, hypoglycemic, and hyperglycemic […]

Posted in -
September 25, 2019
by - admin.

Veeda through its V-Konnect series interacted with Dr. Susobhan Das and discussed about “Current outlook of Biosimilar Development”   About the V- Konnect   V-Konnect interview series, is a program to get in touch with specialized industry experts to know their views on opinions on current relevant subject matters.   About Dr Susobhan Das – […]

Posted in -
August 09, 2019
by - admin.

Veeda through its V-Konnect series interacted with Dr. Ashok Kumar and discussed about “Current Outlook of Indian Pharmaceutical industry”   About the V- Konnect V-Konnect interview series, is a program to get in touch with specialized industry experts to know their views on opinions on current relevant subject matters.   About Dr. Ashok Kumar – […]

Posted in -
July 30, 2019
by - admin.

Conducting a clinical trial is a complex and challenging task and involves robust scientific understanding and logistics planning. Although there are international guidelines for good clinical practices, the standard approach may not work for all clinical trials especially in the case of trials that use orphan drugs, terminally ill patients, epidemiological trials, and so on. […]

Posted in -
July 15, 2019
by - admin.

Veeda through its V-Konnect series interacted with Dr. Arun Bhatt and discussed about “Clinical Trials in India and its regulatory perspective with New CT rules” About the V- Konnect V-Konnect interview series, is a program to get in touch with specialized industry experts to know their views on opinions on current relevant subject matters. About […]

Posted in -
July 09, 2019
by - admin.

Many respiratory diseases have been historically treated using inhalation drugs as this route of administration allows for a higher drug concentration to reach the target organ thereby reducing systemic effects. Apart from respiratory disorders, trials are ongoing to determine the efficacy of inhaled insulin in diabetes management.1,2 Although pulmonary delivery of insulin is a valuable […]

Posted in -
June 29, 2019
by - admin.

In the clinical research industry, safety norms and processes should be applied to every aspect, starting from drug development to post-marketing use of approved drugs, keep in mind patient safety and data credibility at every stage of clinical development. Patient safety requires collaborative effort of the regulatory system, healthcare system, and the sponsor. Equally important […]

Posted in -
June 20, 2019
by - admin.

Shaping of a regulatory framework specific to the Indian clinical market As India emerges as one of the leaders in production of generic pharmaceuticals, contributing to approximately 20% of the global market1, it is necessary to have regulatory authorities approve of more number of drugs or clinical trials to address the burden of diseases prevalent […]

Posted in -
June 20, 2019
by - admin.

India is rapidly gaining acceptance globally as the go-to destination for clinical research. The country offers the advantages of having experienced personnel, good infrastructure such as well-equipped hospitals and laboratories, and a diverse patient pool. Moreover, the increase in life expectancy rate to 65 years and above gives rise to a host of lifestyle diseases […]

Next Entries »